Monday, 28 August 2017

Common treatment for early prostate cancer may carry heart risk

A new study conducted on 7,600 men with early stage prostate cancer suggests that androgen-deprivation therapy may increase the risk for heart failure.  According to study author Reina Haque, a researcher with Kaiser Permanente, "patients should consider heart-healthy lifestyle changes, and physicians should actively monitor the patient's health for early signs of heart disease."  Dr. Nachum Katlowitz, director of urology at Staten Island University Teaching Hospital in New York City agrees with Haque; his reasoning is that all treatments carry potential side effects, however "if androgen-deprivation therapy increases the risk of dying from cardiovascular disease, but decreases the risk of dying from prostate cancer, then we use it."

To read more about this study, click here.

No comments:

Post a Comment